Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 4/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.46 |
| ▸ | TEK | Q02763 | 4/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12227604 | 0.84 | GDA (0.45) | SPHK2SPHK1ALDH1A1RAB9ANPC1 | |
| SCHEMBL12227599 | 0.84 | GDA (0.45) | SPHK2SPHK1ALDH1A1RAB9ANPC1 | |
| SCHEMBL5352883 | 0.82 | XDH (0.67) | SPHK2SPHK1ALDH1A1RAB9ANPC1 | |
| SCHEMBL8535455 | 0.80 | XDH (0.67) | ALDH1A1XDHKDM4E | |
| SCHEMBL249648 | 0.78 | XDH (0.66) | ALDH1A1XDHKDM4ELMNAPOLB | |
| SCHEMBL7160631 | 0.78 | SPHK2 (0.55) | SPHK2SPHK1ALDH1A1RAB9ANPC1 | |
| SCHEMBL12227605 | 0.78 | TSHR (0.44) | ALDH1A1SMN1; SMN2XDHHPGDGDA | |
| SCHEMBL219477 | 0.77 | GDA (0.62) | ALDH1A1SMN1; SMN2KDM4EHPGDGDA | |
| Stearic Acid SCHEMBL6163127 | 0.77 | AKR1B1 (0.49) | ALDH1A1KDM4EHSD17B10GLALMNA | |
| SCHEMBL2623143 | 0.77 | XDH (0.65) | ALDH1A1XDHKDM4EGLALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307166-B1 | Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-20040235782-A1 | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis | PRO-NEURON, INC. | 2004-11-25 | — | — | US | disclosed |
| EP-1157698-A2 | Treatment of inflammatory diseases with oxypurine nucleosides | PRO-NEURON, INC. (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6060459-A | Enhancing blood cell count with oxypurine nucleosides | PRO-NEURON, INC. (US) | 2000-05-09 | — | — | US | disclosed |
| US-6054441-A | Antiinflammatory agents; treatment of bacterial, viral or fungal infections; autoimmune diseases | PRO-NEURON, INC. (US) | 2000-04-25 | — | — | US | disclosed |
| EP-0771204-A4 | METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES | PRO NEURON INC (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0771204-A1 | METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996004923-A1 | METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235782-A1 | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis | TPMT, NUDT1, ENTPD5 | SPHK2 1852/4885SPHK1 1860/4885ALDH1A1 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.